Jan Jongsma joined NutriLeads as VP Supply Chain & Operations

With effect from 16 November 2020 Jan Jongsma joined NutriLeads as VP Supply Chain & Operations. He has a broad experience in the global B-t-B Food and Pharma supply industries. And was active in senior management and executive roles in sourcing & trade, production, logistics, plant investment and procurement. For many years he has worked at FrieslandCampina and more recently for Farm Frites International and Custom Management. 

We are very happy that Jan has joined NutriLeads as he brings very relevant and complimentary experience to the company.

Share

Publication of scientific results on gut microbiome modulation

One of NutriLeads’ health ingredients derived from carrot fibre, i.e. cRG-I, has been assessed for its prebiotic properties using an original combination of in vitro models that mimic parts of the human intestinal tract and the promising results have been published in a peer-reviewed scientific journal (Van den Abbeele et al, Nutrients 2020, 12(7), 1917; https://doi.org/10.3390/nu12071917).

As expected for a prebiotic ingredient, cRG-I is not digested in conditions mimicking the upper intestinal tract of humans but rather rapidly fermented by the gut microbiota. Using a well-established in vitro model to study how the ingredient impacts the human colonic bacteria, it was shown that cRG-I leads to increased production of beneficial short chain fatty acids reputed for their importance in gut health.  Moreover, cRG-I is increasing the abundance of health beneficial bacteria such as bifidobacteria or bacteria displaying anti-inflammatory properties. In addition, the compounds resulting from the fermentation of cRG-I by the gut microbiota were shown to protect the gut barrier against an inflammatory stress in vitro. As a next step, these findings have to be confirmed in human studies but these promising pre-clinical results fully support to pursue further exploration of the health benefits provided by cRG-I and how it acts on the host immune system alongside with its capacity to beneficially modulate the microbiome.

This work was executed in collaboration with Prodigest BV as part of the European Union’s Horizon 2020 research and innovation programme under grant agreements No 811592 and Eurostars E! 10574-NIMF.

Share

Changes NutriLeads’ Supervisory Board

Following the closing of Series B the composition of Nutrileads’ Supervisory Board has been changed. After nearly 5 years, Rudy Mareel stepped down as Chairman of the Board and Sanne Melles was selected as new Chairman. Nityen Lal joined the existing Board members, Florentine Fockema Andreae, Michel Briejer and Rob Beudeker who all remain in function.

We would like to take this opportunity to thank Rudy Mareel for his years of commitment to NutriLeads. He became chairman during the Seed Round and helped Nutrileads through an important phase of its existence including the closing of the Series A and B funding rounds. Thanks to his experience as seasoned executive in the food and healthcare industry with extensive strategic, operational and change management experience in senior leadership roles, he proved to be a strong and dedicated support to the NutriLeads management team.

A special welcome to Sanne Melles, the new Chairman of the Board. Sanne developed his interest and expertise in the food ingredients and biotech industry through multiple executive and non-executive board positions in biotech and food ingredient companies. In addition, he advises various start-ups developing next generation food ingredients. Most recently, Sanne as CEO was responsible for the successful exit of CSK food enrichment to DSM. Sanne’s experience and network will be a great asset to Nutrileads in the next phase of the company and we look forward to working with him.

Share

Self-affirmed General Recognition of Safety for Xtramune™

NutriLeads has received positive feedback from an independent panel of experts that assessed the safety of its unique carrot-derived fiber that is specifically enriched for the rhamnogalacturonan-I pectin fraction, branded Xtramune™. It is NutriLeads’ first health ingredient planned for commercialization.

The expertpanel concluded that the dossier, which reviews and summarizes all the available scientific evidence on manufacturing, uses and toxicology, clearly demonstrates the safety of the ingredient. They, therefore, supported the intended use in the proposed food categories. This is an important milestone as it enables NutriLeads to market Xtramune™ in the USA.

Richard Lane, Ph.D. from Lane Toxicology Consulting, who prepared the dossier on behalf of NutriLeads, indicates: “NutriLeads made a great effort to substantiate the stability and safety of their first food ingredient. It has been a pleasure to prepare the dossier and to organize the expert panel review for them.”

Earlier this year, NutriLeads submitted a Novel Foods dossier to EFSA in order to prepare for market access in Europe and is awaiting feedback and questions from the agency.

Share

NutriLeads attracts Series B funding to launch its innovative immune-enhancing ingredient, Xtramune™, and to progress its portfolio of health ingredients

3 September, 2020

Dutch Health Ingredients company, NUTRILEADS BV, announces the closing of a Series B financing round of 6.5 m€, led by ICOS CAPITAL together with GOEIE-GRUTTEN and existing shareholders DSM VENTURING, OOST NL, SHIFT INVEST and THUJA.

NutriLeads, established in 2012, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, XtramuneTM, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections.

This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving XtramuneTM towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans.

Ruud Albers, CEO of NutriLeads indicates: “We are very excited about this successful funding round which helps to propel NutriLeads forward. People can strengthen their health with nutrition. It is our ambition to unlock the potential of clinically proven food ingredients and this funding round supports that mission. It is great to see that all our investors are committed to this shared goal.”

Nityen Lal, Managing Director of ICOS Capital Management BV: “Health ingredients are sought-after by food companies and their consumers. NutriLeads has impressed us by its professionalism, the quality of the work done and their network in the industry. We are confident that this is a worthwhile investment both for our LPs as well as for the consumers who will benefit from the health ingredients to be marketed.”

Share

Sweet Crosstalk project started

Nutrileads is a partner in the Sweet Crosstalk, a multidisciplinary European Innovative Training Network built to address the challenge at a molecular level how glycans are involved at the human mucosa microbiota interface, and how this correlates with human well-being. In the network the expertise ranges from chemical synthesis, biochemistry, structural biology to microbiology and cell biology.

Early 2020 Krishna Desai started in the PhD-position to unravel the structure-function of pectin derived polysaccharides by studying the interaction of purified and modified variants with the host immune system and their impact on the human gut microbiota. Nutrileads collaborates in this with partners at Utrecht University, University of Helsinki and the Quadram Institute.

Share

NutriLeads invited to join ScaleUpFood Program of ScaleUpNation

October 29th, 2019, Wageningen, the Netherlands

Nutrileads is excited to join the ScaleUpFood Program of ScaleUpNation, a program for ventures built to empower the venture founders team through the transition from start-up to scale- up. Through transformational experiences in the Runway and ScaleUpFood and comprehensive leadership coaching and content sprints in the Flight Program, ventures maximize their chances to scale. For more information: https://scaleupnation.com/programs/scaleup-food/

 

Share

PhD position for Sweet Crosstalk (CLOSED)

 
NutriLeads is partner in the Sweet Crosstalk, a multidisciplinary European Innovative Training Network built to address the challenge of understanding, at a molecular level, how glycans are involved at the human mucosa–microbiota interface, and how this correlates with human well-being. The research strategy of the Sweet Crosstalk program focuses on optimal synergy between chemistry and biology. In the network the expertise ranges from chemical synthesis, biochemistry, structural biology to microbiology and cell biology.

15 positions were open for talented and motivated candidates to become Sweet Crosstalk PhD students covering different aspects of innovative glyco- and microbiome sciences. One of these positions (ESRA14) is co-directed by Utrecht University and NutriLeads, with short secondments at University of Helsinki (Finland) and Quadram Institute (UK). The aim of this PhD position is to unravel the structure-function of pectin derived polysaccharides by studying the interaction of purified and modified variants with the host immune system and their impact on the human gut microbiota.

For the ESRA14 position, we are currently looking for a talented and motivated candidate with:

  • Experience and/or knowledge of analytical chemistry preferably linked to microbiota and/or signalling to the host
  • A good command of the English language
  • Team spirit for collaborating with partners at Utrecht University, University of Helsinki and the Quadram Institute

Applications in English should be sent by e-mail to info@nutrileads.com and contain:

    • Short motivation letter (2 pages max.)
    • CV and copies of the Master diploma including marks
    • Two recommendation letters or the contact information of 1-2 referees

Please cite in your application: ESRA14 PhD project
Application deadline: October 31st, 2019
For more information about Sweet Crosstalk visit: www.sweetcrosstalk.eu

*Please note that application is only possible for this PhD position (ESRA14) via email, application for the other 14 positions from the Sweet Crosstalk is closed.

Funding Programme H2020 Marie Skłodowska-Curie ITN 2018

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 814102.

Share